Lorraine A Fitzpatrick
Overview
Explore the profile of Lorraine A Fitzpatrick including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
67
Citations
1869
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dhaliwal R, Hans D, Hattersley G, Mitlak B, Fitzpatrick L, Wang Y, et al.
JBMR Plus
. 2021 Feb;
5(2):e10414.
PMID: 33615100
[This corrects the article DOI: 10.1002/jbm4.10346.].
2.
Miller P, Bilezikian J, Fitzpatrick L, Mitlak B, McCloskey E, Cosman F, et al.
Curr Med Res Opin
. 2020 Sep;
36(11):1861-1872.
PMID: 32969719
Objective: Fractures due to osteoporosis represent a serious burden on patients and healthcare systems. The objective of this review is to provide an overview of the anabolic agent abaloparatide (ABL)...
3.
Greenspan S, Fitzpatrick L, Mitlak B, Wang Y, Harvey N, Deal C, et al.
Menopause
. 2020 Jul;
27(10):1137-1142.
PMID: 32665529
Objective: Fracture risk increases with age, but few studies focus on persons ≥80 years. In the ACTIVE trial, treatment with abaloparatide for 18 months reduced osteoporotic fracture risk and increased...
4.
Dhaliwal R, Hans D, Hattersley G, Mitlak B, Fitzpatrick L, Wang Y, et al.
JBMR Plus
. 2020 Apr;
4(4):e10346.
PMID: 32258965
Type 2 diabetes mellitus (T2DM) increases fracture risk despite normal or increased BMD. Abaloparatide reduces fracture risk in patients with postmenopausal osteoporosis (PMO); however, its efficacy in women with T2DM...
5.
Hiligsmann M, Williams S, Fitzpatrick L, Silverman S, Weiss R, Reginster J
Semin Arthritis Rheum
. 2020 Mar;
50(3):394-400.
PMID: 32160943
Objectives: Emerging evidence supports sequential therapy with anabolic followed by antiresorptive in patients at high-risk of fragility fractures. This study assessed the cost-effectiveness of sequential treatment with abaloparatide (ABL) followed...
6.
Deal C, Mitlak B, Wang Y, Fitzpatrick L, Miller P
Bone Rep
. 2019 Dec;
11:100230.
PMID: 31799340
Abaloparatide is a selective activator of the parathyroid hormone type 1 receptor signaling pathway that favors the stimulation of bone formation. Here, we report a prospective, exploratory analysis of bone...
7.
Bilezikian J, Hattersley G, Mitlak B, Hu M, Fitzpatrick L, Dabrowski C, et al.
Curr Med Res Opin
. 2019 Aug;
35(12):2097-2102.
PMID: 31418585
To evaluate, post hoc, the efficacy and safety of abaloparatide by degree of renal impairment. ACTIVE was a phase 3, 18-month, randomized, double-blind, active-comparator, placebo-controlled study of postmenopausal women with...
8.
Hiligsmann M, Williams S, Fitzpatrick L, Silverman S, Weiss R, Reginster J
Semin Arthritis Rheum
. 2019 Feb;
49(2):184-196.
PMID: 30737062
Objectives: There is emerging evidence supporting sequential therapy with an osteoanabolic followed by an antiresorptive in patients at high-risk of fragility fractures. This study assessed the cost-effectiveness of sequential treatment...
9.
Reginster J, Hattersley G, Williams G, Hu M, Fitzpatrick L, Lewiecki E
Calcif Tissue Int
. 2018 Jun;
103(5):540-545.
PMID: 29951742
Abaloparatide (ABL) is a 34-amino acid peptide designed to be a selective activator of the parathyroid hormone receptor type 1 signaling pathway. In the Abaloparatide Comparator Trial In Vertebral Endpoints...
10.
Bone H, Cosman F, Miller P, Williams G, Hattersley G, Hu M, et al.
J Clin Endocrinol Metab
. 2018 May;
103(8):2949-2957.
PMID: 29800372
Purpose: In women with postmenopausal osteoporosis, we investigated the effects of 24 months of treatment with alendronate (ALN) following 18 months of treatment with abaloparatide (ABL) or placebo (PBO). Methods:...